- ￥400 - 800
- MedChemExpress(MCE)
- 美国
- HY-B0227
- 2025年12月05日
企业认证
相关产品推荐更多 >
![5-[(3,5-Dicarboxyphenyl)methyl]benzene-1,3-dicarboxylic acid,10397-52-1](https://img1.dxycdn.com/p/s14/2026/0701/189/8697471869001522702.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
从原料到标记，打造属于中国自己的流式抗体品牌推荐！临床医学研究优质期刊，覆盖29个领域五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
RP-19583
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
22071-15-4
- 规格：
10 mM * 1 mL/500 mg/1 g/5 g
| 规格： | 10 mM * 1 mL | 产品价格： | ￥500.0 |
|---|---|---|---|
| 规格： | 500 mg | 产品价格： | ￥400.0 |
| 规格： | 1 g | 产品价格： | ￥500.0 |
| 规格： | 5 g | 产品价格： | ￥800.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Ketoprofen
CAS No. : 22071-15-4
MCE 国际站：Ketoprofen
产品活性：Ketoprofen (RP-19583) 是一种非甾体抗炎剂，可抑制 cyclooxygenase 的活性，其 IC50 值为 2 nM (COX-1) 和 26 nM (COX-2)。Ketoprofen 可用于炎症、免疫学和代谢性疾病 (如肥胖) 的相关研究。
作用靶点：COX
In Vitro: Ketoprofen inhibits COX in LPS-stimulated monocytes isolated from human blood, with IC50 values of 2 nM (COX-1) and 26 nM (COX-2).
Ketoprofen (2.5 mg /mL, 3-24h) decreases the mRNA level of immune factors (TNFα, IL-8, SAA and COX-2) and PTGES in LPS-stimulated bovine mammary epithelial cells.
In Vivo: Ketoprofen (Oral administration, 10 mg/kg, three times a week for 10 weeks, HFD-induced obese C57BL/6 mice) decreases in relative body weight (15.41%), the iWAT mass (approximately 41%), and leptin (58.68%) and resistin (12.88%).
Ketoprofen (50 mg/kg, LPS-treated dairy cows) lowers the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk induced by LPS.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Pyroptosis Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | Antidepressant Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Withdrawn Drug Compound Library | Off-patent Drug Library | Mitochondrial Toxicity Compound Library | Highly Selective Inhibitors Library | Acetaminophen | Indomethacin | Celecoxib | EIPA | Aspirin | Oxidopamine hydrobromide | Deferiprone | Diclofenac | Gallic acid | Ibuprofen | Catechin | 20(S)-Ginsenoside Rg3 | Cucurbitacin B | Carprofen | Meloxicam | (-)-Epicatechin | NS-398 | Naproxen | Xanthohumol | Flufenamic acid | Salicylic acid | Phenacetin | SC-560 | Rebamipide | Ginsenoside Rd | Niflumic acid
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验停药。 本类药物中的萘普生（naproxen）及酮洛芬（ketoprofen）的作用及用途均相似，但t 1/2 分别为12～15小时和2小时。 吡罗昔康 吡罗昔康（piroxicam,炎痛喜康）属苯噻嗪类。口服吸收完全，2～4小时血药浓度达峰值。在体外抑制PG合成酶的效力与吲哚美辛相等。对风湿性及类风湿性关节炎的疗效与乙酰水杨酸、吲哚美辛及萘普生相同而不良反应少，患者耐受良好。其主要优点是血浆t
水杨酸，但主要特点是胃肠反应较轻，易耐受。 不良反应有轻度消化不良、皮疹；胃肠出血不常见，但长期服用者仍应注意；偶见视力模糊及中毒性弱视，出现视力障碍者应立即停药。 本类药物中的萘普生（naproxen）及酮洛芬（ketoprofen）的作用及用途均相似，但t 1/2 分别为12～15小时和2小时。 吡罗昔康 吡罗昔康（piroxicam,炎痛喜康）属苯
Guidelines for the Use of Anesthetics, Analgesics and Tranquilizers in Laboratory Animals
by several techniques. Anesthetic effects are seen within 15 minutes of administration and may last from 45 minutes to several hours, depending on the drug used. Infiltration or infusion- injection beneath the skin and other tissue layers
技术资料暂无技术资料 索取技术资料
